40929-48-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Pyrimidinecarbonyl chloride (7CI,9CI) is used as a carbonylating agent for the synthesis of various pharmaceutical compounds. Its reactivity allows for the introduction of carbonyl groups into organic molecules, facilitating the production of a wide range of drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Pyrimidinecarbonyl chloride (7CI,9CI) serves as a key intermediate in the synthesis of various agrochemicals. Its ability to introduce carbonyl groups into organic molecules contributes to the development of effective pesticides, herbicides, and other agricultural chemicals.
Used in Organic Synthesis:
5-Pyrimidinecarbonyl chloride (7CI,9CI) is employed as a versatile reagent in organic synthesis. Its high reactivity enables the formation of carbonyl groups in a variety of organic molecules, making it a valuable tool for the synthesis of complex organic compounds and the development of new chemical entities.
Used in Research and Development:
In research and development settings, 5-Pyrimidinecarbonyl chloride (7CI,9CI) is utilized for exploring new chemical reactions and developing innovative synthetic routes. Its unique reactivity allows researchers to investigate novel chemical transformations and expand the scope of organic synthesis.
Used in Academic Education:
5-Pyrimidinecarbonyl chloride (7CI,9CI) is also employed as a teaching aid in academic institutions, where it is used to demonstrate the principles of electrophilic aromatic substitution and the introduction of functional groups in organic chemistry. 5-Pyrimidinecarbonyl chloride (7CI,9CI) provides students with hands-on experience in handling reactive compounds and understanding their applications in various chemical processes.

InChI:InChI=1/C5H3ClN2O/c6-5(9)4-1-7-3-8-2-4/h1-3H

Upstream product

• 4595-61-3 pyrimidine-5-carboxylic acid 

Downstream Products

• 98405-54-0 N,N-dimethyl-5-pyrimidinecarboxamide 
• 861905-60-4 (4-bromo-2-fluorophenyl)(5-pyrimidinyl)methanone 
• 1254973-35-7 C₁₅H₁₄N₂O₅ 
• 133510-27-7 3-phenyl-1-(pyrimidin-5-yl)prop-2-yn-1-one 
• 1361189-90-3 5-{3-[1-(4-bromophenyl)cyclobutyl]-[1,2,4]oxadiazol-5-yl}pyrimidine 
• 1361187-90-7 5-{4-[1-(5-pyrimidin-5-yl-[1,2,4]oxadiazol-3-yl)cyclobutyl]phenyl}pyrimidin-2-ylamine 
• 40929-49-5 pyrimidine-5-carboxamide 

Relevant academic research and scientific papers

N-(indol-5-yl) aromatic heterocyclic amide compound and preparation method and application thereof

The invention belongs to the field of medicines, and relates to an N-(indole-5-yl) aromatic heterocyclic amide compound and a preparation method and application thereof. The structural general formula of the N-(indol-5-yl) aromatic heterocyclic amide compound is shown in the specification. A pharmaceutical composition comprises the N-(indol-5-yl) aromatic heterocyclic amide compound, a pharmaceutically acceptable salt, a hydrate or a solvate of the N-(indol-5-yl) aromatic heterocyclic amide compound and a pharmaceutically acceptable carrier of the N-(indol-5-yl) aromatic heterocyclic amide compound. The invention further discloses application of the N-(indol-5-yl) aromatic heterocyclic amide compound or the pharmaceutically acceptable salt, hydrate or solvate thereof or the pharmaceutical composition in preparation of anti-hyperuricemia and anti-gout drugs. Tests prove that the compound shows a good effect in an in-vitro xanthine oxidase inhibitory activity test. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

Amide-based xanthine oxidase inhibitors bearing an N-(1-alkyl-3-cyano-1H-indol-5-yl) moiety: Design, synthesis and structure-activity relationship investigation

Our previous work identified a promising isonicotinamide based xanthine oxidase (XO) inhibitor, N-(3-cyano-4-((2-cyanobenzyl)oxy)phenyl)isonicotinamide (1), and concluded that amide is an effective linker in exploring the XO inhibitor chemical space that is completely different from the five-membered ring framework of febuxostat and topiroxostat. Indole, an endogenous bioactive substance and a popular drug construction fragment, was involved in the structural optimization campaign of the present effort. After the installation of some functional groups, N-(1-alkyl-3-cyano-1H-indol-5-yl) was generated and employed to mend the missing H-bond interaction between the 3′-cyano of 1 and Asn768 residue of XO by shortening their distance. In this context, eight kinds of heterocyclic aromatic amide chemotypes were rationally designed and synthesized to investigate the structure-activity relationship (SAR) of amide-based XO inhibitors. The optimized compound a6 (IC50 = 0.018 μM) exhibits 17.2-fold improved potency than the initial compound 1 (IC50 = 0.31 μM). Its potency is comparable to that of topiroxostat (IC50 = 0.013 μM). Molecular docking and molecular dynamics studies proved the existence of the stable H-bond between the cyano group and the Asn768 residue. Moreover, oral administration of a6 (11.8 mg/kg) could effectively reduce serum uric acid levels in an acute hyperuricemia rat model. Liver microsomal stability assay illustrated that compound a6 possesses well metabolic stability in rat liver microsomes. However, the in vivo potency of a6 was much lower than that of topiroxostat, which may be explained by the poor absorption found in the parallel artificial membrane permeability assay (PAMPA). In addition, 6a has non-cytotoxicity against normal cell lines MCF10A and 16HBE. Taken together, this work culminated in the identification of compound 6a as an excellent lead for further exploration of amide-based XO inhibitors.

Synthesis of N-trifluoromethyl amides from carboxylic acids

Found in biomolecules, pharmaceuticals, and agrochemicals, amide-containing molecules are ubiquitous in nature, and their derivatization represents a significant methodological goal in fluorine chemistry. Trifluoromethyl amides have emerged as important functional groups frequently found in pharmaceutical compounds. To date, there is no strategy for synthesizing N-trifluoromethyl amides from abundant organic carboxylic acid derivatives, which are ideal starting materials in amide synthesis. Here, we report the synthesis of N-trifluoromethyl amides from carboxylic acid halides and esters under mild conditions via isothiocyanates in the presence of silver fluoride at room temperature. Through this strategy, isothiocyanates are desulfurized with AgF, and then the formed derivative is acylated to afford N-trifluoromethyl amides, including previously inaccessible structures. This method shows broad scope, provides a platform for rapidly generating N-trifluoromethyl amides by virtue of the diversity and availability of both reaction partners, and should find application in the modification of advanced intermediates.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma

We previously demonstrated that some N-biphenylanilides caused cell-cycle arrest at G2/M transition in breast cancer cells. Among them we choose three derivatives, namely PTA34, PTA73 and RS35 for experimentation in solid tumor cell lines, classical Hodgkin Lymphoma (cHL) cell lines and bona fide normal cell lines. Almost all tumor cells were sensitive to compounds in the nanomolar range whereas, they were not cytotoxic to normal ones. Interestingly the compounds caused a strong G2/M phase arrest in cHL cell lines, thus, here we investigated whether they affected the integrity of microtubules in such cells. We found that they induced a long prometaphase arrest, followed by induction of apoptosis which involved mitochondria. PTA73 and RS35 induced the mitotic arrest through the fragmentation of microtubules which prevented the kinethocore-mitotic spindle interaction and the exit from mitosis. PTA34 is instead a tubulin-targeting agent because it inhibited the tubulin polymerization as vinblastine. As such, PTA34 maintained the Cyclin B1-CDK1 regulatory complex activated during the G2/M arrest while inducing the inactivation of Bcl-2 through phosphorylation in Ser70, the degradation of Mcl-1 and a strong activation of BIML and BIMS proapoptotic isoforms. In addition PTA34 exerted an antiangiogenic effect by suppressing microvascular formation.

Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: Discovery of 2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]- N, N -dimethyl-acetamide (BI 665915)

The synthesis, structure-activity relationship (SAR), and evolution of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are described. The use of structure-guided drug design techniques provided compounds that demonstrated excellent FLAP binding potency (IC50 4 synthesis in human whole blood (IC50 4 production.

Catalytic syntheses of N-heterocyclic ynones and ynediones by in situ activation of carboxylic acids with oxalyl chloride

Breaking the bottleneck: α-Keto carboxylic acids and N-heterocyclic carboxylic acids are activated in situ with oxalyl chloride then catalytically alkynylated to give ynediones and N-heterocyclic ynones efficiently in a one-pot fashion. 5-Acylpyrazoles and 2-phenylaminopyrimidines, potentially interesting for pharmaceutical applications, are readily synthesized in concise one-pot, three-component syntheses. Copyright

NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF

The invention relates to 1,2,4 oxadiazole compounds and analogs thereof, represented by formula (II), and compositions and methods of use thereof.

PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Disclosed are CRTH2 inhibitors represented by Structural Formula (I). The values for the variables of Structural Formula (I) are provided herein.

Novel compounds useful for bradykinin B1 receptor antagonism

Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the